Evidence map›Paper›PMID 40140179›Full record

Trial reportTargeted oncology2025

A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors.

Cathy Eng, Nehal J Lakhani, Philip A Philip, Charles Schneider, Benny Johnson, Adel Kardosh, Mark P Chao, Amita Patnaik, Fadi Shihadeh, Yeonju Lee and 6 more

Registry-linked trialAbstract readClinical Trial, Phase IMulticenter StudyClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Targeted oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02953782 (A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer), which is not on this map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02953782 phase1 / phase2completednot on this map

A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer

TypeinterventionalSponsorGilead SciencesRan2016 to 2020Enrolled78ConditionsSolid Tumor, Colorectal CancerArmsMagrolimab, Cetuximab
3 · Its place in the literature

Who cites it

31 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. CD47 and FOXP3Cancers · 2026
    Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Cathy EngDivision of Hematology/Oncology, Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. cathy.eng@vumc.org.
Nehal J LakhaniThe START Center for Cancer Research, Grand Rapids, MI, USA.
Philip A PhilipDivision of Hematology-Oncology, Department of Medicine, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
Charles SchneiderAbramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Benny JohnsonDepartment of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Adel KardoshDivision of Medical Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Mark P ChaoForty Seven, Inc, Menlo Park, CA, USA.
Amita PatnaikThe START Center for Cancer Research, San Antonio, TX, USA.
Fadi ShihadehGilead Sciences, Inc, Foster City, CA, USA.
Yeonju LeeGilead Sciences, Inc, Foster City, CA, USA.
Kai SongGilead Sciences, Inc, Foster City, CA, USA.
Denise JinGilead Sciences, Inc, Foster City, CA, USA.
Yanan HuoGilead Sciences, Inc, Foster City, CA, USA.
Michael HowlandGilead Sciences, Inc, Foster City, CA, USA.
George A FisherDivision of Medical Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
J Randolph HechtDivision of Hematology/Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChemotherapy plus epidermal growth factor receptor (EGFR) inhibitors, such as cetuximab, is standard therapy for KRAS wild-type (KRASwt) colorectal cancer (CRC); however, responses are infrequent. Magrolimab is a monoclonal antibody targeting CD47, an antiphagocytic signal overexpressed in solid tumors (STs).

objectiveThis open-label, multicenter phase 1b/2 study (NCT02953782) aimed to determine the recommended phase 2 dose (RP2D) and evaluate the safety, tolerability, and efficacy of magrolimab + cetuximab in patients with advanced CRC or other STs. PATIENTS AND

methodsA total of 78 patients were enrolled at eight study sites in the USA. In phase 1b, patients with advanced STs received weekly maintenance doses of magrolimab at 10-45 mg/kg and cetuximab at 200-250 mg/m

resultsThe maximum tolerated dose was not reached in phase 1b. Two RP2Ds were explored in phase 2: magrolimab at 30 or 45 mg/kg plus cetuximab at 250 mg/m

conclusionsThese results indicate tolerability and potential antitumor activity when combining anti-CD47 therapy and cetuximab in heavily pretreated patients with CRC.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCD47 AntigenCetuximabColorectal NeoplasmsNeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedAntibodies, Monoclonal, HumanizedCD47 AntigenCetuximab

Identifiers

PMID40140179
PMCPMC12106125

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.